Lauro José Gregianin
Universidade Federal do Rio Grande do Sul
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Lauro José Gregianin.
Jornal De Pediatria | 2001
Cláudio Galvão de Castro Junior; Lauro José Gregianin; Algemir Lunardi Brunetto
Objective: to review the indications, main steps and complications of bone marrow transplantation in children. Sources: Medline-based literature review. Summary of the findings: we comment about the indications of autologous, allogeneic and syngeneic bone marrow transplantation, donor selections, harvest and infusion of the hematopoietic progenitor cells that will reconstitute the hematopoietic and immune systems. We describe the different conditioning regimens and the new sources of cells, such as cord blood. We also describe the most common events after the procedure, including infections, graft versus host disease, and cardiovascular, pulmonary, hepatic, genitourinary, and gastrointestinal complications. The late effects and their impact on quality of life are also discussed. Conclusions: bone marrow transplantation does not confer an absolutely normal life span to all the patients; however, it represents the only chance of cure for children with certain neoplastic or immunological diseases. By knowing the steps of the procedure, pediatricians can be a source of information on bone marrow transplantation to the patients and their families.
Jornal De Pediatria | 2004
Ângela Rech; Cláudio Galvão de Castro; Jane Mattei; Lauro José Gregianin; Luciane Pons Di Leone; Alexandre David; Luis Fernando da Rosa Rivero; Ricardo P Tarragô; Armando de Abreu; Algemir Lunardi Brunetto
OBJECTIVE To identify the clinical features in osteosarcoma and to investigate their influence on the prognosis of children and adolescents presenting this disease. MATERIAL AND METHODS The records of children and adolescents with osteosarcoma treated by the Bone Tumors Group of the state of Rio Grande do Sul, Brazil, between January 1992 and December 2001 were reviewed. RESULTS Fifty consecutive patients were included in this study. Mean age at diagnosis was 13 years (3-22); 68% of the patients were males. The primary site of disease was the femur in 50% of the patients, tibia in 30%, pelvis in 4%, humerus in 10%, fibula in 2% and other sites in 4%. Nineteen patients presented metastases at diagnosis (38%). All patients received chemotherapy and were treated with three different schemes. As for surgical treatment, 26 patients (52%) had an amputation and 17 (34%) received conservative surgery. Serum lactic dehydrogenase > 1,000 UI/ml (p = 0.0159, log rank), tumor necrosis < 90% and presence of metastases had a negative influence on prognosis. The overall 5-year survival was of 33.2+/-7.2% with mean follow-up of 36 months (6-126). Event-free survival was 29.7+/-7%. The 5-year event-free survival in non-metastatic patients was 45+/-10.7%, and zero in metastatic patients (follow-up of 78.4 and 18.7 months, respectively). Only two out of 19 metastatic patients are alive and free of disease at 18 and 30 months respectively. CONCLUSION Metastatic disease at diagnosis, serum levels of serum lactic dehydrogenase > 1,000 UI/ml and tumor necrosis < 90% are predictors of unfavorable prognosis. The excessively high incidence of metastatic patients may suggest the presence of an aggressive pattern of disease in our population, or may indicate late diagnosis.
Brain & Development | 2010
Laura Bannach Jardim; Andrew Chaves Feitosa da Silva; Deborah Blank; Maria Mercedes Villanueva; Luisa Renck; Mariana La Bella Costa; Carmen Regla Vargas; Marion Deon; Daniel la M. Coelho; Leonardo Modesti Vedolin; Cláudio Galvão de Castro; Lauro José Gregianin; Carmem Bonfim; Roberto Giugliani
UNLABELLED X-linked adenoleukodystrophy is a genetic disease that affects the degradation of very long-chain fatty acids. In male patients, common pictures are the cerebral form (CALD), myeloneuropathy (AMN), and Addison-only. OBJECTIVE To describe the clinical course of affected male patients from South Brazil between 1993 and 2007. METHODS Affected male patients and their maternal lineages were studied from a clinical, neurological and biochemical standpoint. RESULTS Eighty-three male patients from 30 families were biochemically evaluated: 51 were affected. 27/51 (54%) presented the cerebral form; 11/51 had AMN (22%); 5 had Addison-only (10%), and 8 (16%) were asymptomatic. Between 2002 and 2006, the minimal incidence was 1:35,000 males in our State (South Brazil). Forty-three affected individuals were followed for 5.4+/-3.7 years. Of 10 boys detected at early stages, three developed CALD. These three boys and another five CALD at baseline were referred to hematopoietic stem cell transplantation. Seven transplants were carried out, 5 with good clinical evolution after 2.2 years post-transplant. The non-transplanted case was later defined as a stable cerebral form. DISCUSSION Among the present families, the observed cases were comparable to the 50% expected by Mendelian segregation. Based on the natural history, the number of cases that developed CALD was similar to the expected. Transplants were successful in 70% of cases. The occurrence of a stable cerebral form pointed to an urgent need for better markers of active cerebral disease.
Jornal De Pediatria | 2009
Ângela Rech Cagol; Cláudio Galvão de Castro Junior; Maria Cristina Martins; Adão Rogério Leal Machado; Renato Chagas Ribeiro; Lauro José Gregianin; Algemir Lunardi Brunetto
OBJECTIVE To compare the use of intravenous vs. oral antibiotic therapy. METHODS All febrile neutropenic patients younger than 18 years old with low risk of complications and receiving chemotherapy were selected. The study was conducted from 2002 to 2005 at the Pediatric Oncology Unit of Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil. Patients were divided into group A and group B and were randomly assigned to receive oral or intravenous therapy. The empirical antimicrobial treatment used for group A consisted in oral ciprofloxacin plus amoxicillin-clavulanate and intravenous placebo, and group B received cefepime and oral placebo. RESULTS A total of 91 consecutive episodes of febrile neutropenia in 58 children were included in the study. For patients of group A, treatment failure rate was 51.2%; the mean length of hospital stay was 8 days (range 2-10 days). For patients treated with intravenous antibiotic therapy, treatment failure rate was 45.8%; the mean length of hospital stay was 7 days (range 3-10 days). CONCLUSION There was no difference in the outcome in oral vs. intravenous therapy. There is need of larger randomized trials before oral empirical therapy administered to this population should be considered the new standard of treatment.
Journal of Pediatric Hematology Oncology | 2003
Cláudio Galvão de Castro; Simone Geiger de Almeida; Lauro José Gregianin; Jiseh Fagundes Loss; Luis Fernando da Rosa Rivero; Gilberto Schwartsmann; Algemir Lunardi Brunetto
Pleuropulmonary blastoma (PPB) is a rare and aggressive malignant tumor of the lung. Approximately 80 cases of PPB have been published, and in only three cases high-dose chemotherapy with autologous hematopoietic stem cell transplantation (HSCT) was applied. A 5-year-old girl presenting with cough, fever, and shortness of breath was referred to the authors in March 1999. A computed tomography scan of the chest showed a tumor mass in the left hemithorax. The lesion was biopsied and the histopathologic report suggested the diagnosis of PPB. The patient received chemotherapy comprising vincristine, actinomycin D, and cyclophosphamide with only a minor response, and treatment was switched to ifosfamide, carboplatin, and etoposide, which produced a partial response. Tumor resection was performed, but margins were positive for PPB. Due to the high risk of recurrence, the authors elected to administrate high-dose chemotherapy using melphalan, etoposide, and carboplatin, followed by autologous HSCT. The patient achieved complete hematologic recovery, and reimaging after HSCT showed no evidence of disease. She relapsed 4 months later and died about 9 months after the completion of high-dose therapy. The role of high-dose chemotherapy and autologous HSCT is likely to be limited in PPB.
Pediatric Blood & Cancer | 2013
Ana Lucia Abujamra; Juliana Ribas Escosteguy; Celso Dall'Igna; Denise Manica; Luciana Facchini Cigana; Patrícia Pérez Coradini; André Tesainer Brunetto; Lauro José Gregianin
Cisplatin may cause permanent cochlear damage by changing cochlear frequency selectivity and can lead to irreversible sensorineural hearing loss. High‐frequency audiometry (HFA) is able to assess hearing frequencies above 8,000 Hz; hence, it has been considered a high‐quality method to monitor and diagnose early and asymptomatic signs of ototoxicity in patients receiving cisplatin.
Jornal De Pediatria | 2009
Ângela Rech Cagol; Cláudio Galvão de Castro Junior; Maria Cristina Martins; Adão Rogério Leal Machado; Renato Chagas Ribeiro; Lauro José Gregianin; Algemir Lunardi Brunetto
OBJECTIVE: To compare the use of intravenous vs. oral antibiotic therapy. METHODS: All febrile neutropenic patients younger than 18 years old with low risk of complications and receiving chemotherapy were selected. The study was conducted from 2002 to 2005 at the Pediatric Oncology Unit of Hospital de Clinicas de Porto Alegre, Porto Alegre, Brazil. Patients were divided into group A and group B and were randomly assigned to receive oral or intravenous therapy. The empirical antimicrobial treatment used for group A consisted in oral ciprofloxacin plus amoxicillin-clavulanate and intravenous placebo, and group B received cefepime and oral placebo. RESULTS: A total of 91 consecutive episodes of febrile neutropenia in 58 children were included in the study. For patients of group A, treatment failure rate was 51.2%; the mean length of hospital stay was 8 days (range 2-10 days). For patients treated with intravenous antibiotic therapy, treatment failure rate was 45.8%; the mean length of hospital stay was 7 days (range 3-10 days). CONCLUSION: There was no difference in the outcome in oral vs. intravenous therapy. There is need of larger randomized trials before oral empirical therapy administered to this population should be considered the new standard of treatment.
Oncotarget | 2016
Tiago Elias Heinen; Rafael Pereira dos Santos; Amanda Rocha; Michel Pinheiro dos Santos; Patrícia Luciana da Costa Lopez; Marco Aurélio Silva Filho; Bárbara Kunzler Souza; Luis Fernando da Rosa Rivero; Ricardo Gehrke Becker; Lauro José Gregianin; Algemir Lunardi Brunetto; André Tesainer Brunetto; Caroline Brunetto de Farias; Rafael Roesler
Ewing sarcoma (ES) is a highly aggressive pediatric cancer that may arise from neuronal precursors. Neurotrophins stimulate neuronal devlopment and plasticity. Here, we found that neurotrophins nerve growth factor (NGF) and brain-derived neurotrophic factor (BDNF), as well as their receptors (TrkA and TrkB, respectively) are expressed in ES tumors. Treatment with TrkA (GW-441756) or TrkB (Ana-12) selective inhibitors decreased ES cell proliferation, and the effect was increased when the two inhibitors were combined. ES cells treated with a pan-Trk inhibitor, K252a, showed changes in morphology, reduced levels of β-III tubulin, and decreased mRNA expression of NGF, BDNF, TrkA and TrkB. Furthermore, combining K252a with subeffective doses of cytotoxic chemotherapeutic drugs resulted in a decrease in ES cell proliferation and colony formation, even in chemoresistant cells. These results indicate that Trk inhibition may be an emerging approach for the treatment of ES.
International Journal of Laboratory Hematology | 2015
Iuri Vicente Camargo Morkis; Mariela Granero Farias; Lisandra Della Costa Rigoni; Luciana Scotti; Lauro José Gregianin; Liane Esteves Daudt; L. M. da R. Silla; Alessandra Aparecida Paz
Engraftment is a critical milestone of the hematopoietic stem cell transplantation (HSCT) process. The immature platelet fraction (IPF) and immature reticulocyte fraction (IRF) are considered early indicators of bone marrow recovery. The objective of this study was to assess these parameters as predictors of HSCT engraftment.
Pediatric Blood & Cancer | 2015
Algemir Lunardi Brunetto; Luis Castillo; Antonio Sergio Petrilli; Carla Renata Donato Pacheco Macedo; Erica Boldrini; Cecília da Costa; Maria T. Almeida; Daniela Kirst; Carlos Rodriguez-Galindo; Waldir Veiga Pereira; Flora Watanabe; Maria Pizza; Eliana Benites; Vera Lúcia Lins de Morais; Andréa Gadelha; Antônio Nakasato; Ana Lucia Abujamra; Lauro José Gregianin
Large cooperative group studies have shown the efficacy of risk‐adapted treatment for Ewing sarcoma. However, validation and local adaptation by National cooperative groups is needed. A multicenter protocol to determine the efficacy and safety of a risk‐adapted intensive regimen was developed by the Brazilian cooperative group.
Collaboration
Dive into the Lauro José Gregianin's collaboration.
Cláudio Galvão de Castro Junior
Universidade Federal do Rio Grande do Sul
View shared research outputsSimone Geiger de Almeida Selistre
Universidade Federal do Rio Grande do Sul
View shared research outputsMario Correa Evangelista Junior
Universidade Federal do Rio Grande do Sul
View shared research outputs